HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on PDS Biotechnology (NASDAQ:PDSB) and maintained a $21 price target.
August 01, 2024 | 8:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on PDS Biotechnology and maintained a $21 price target.
The reiteration of a Buy rating and the maintenance of a $21 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100